arrow
A

Alessandro Morabito

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
H指数:55
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study

在晚期非小细胞肺癌中免疫疗法停药两年的真实世界结局:I-STOP研究的最终结果

2026-02-190
PRE
Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patients

患者报告结局的不良事件常用术语标准(PRO-CTCAE)在意大利肺癌患者中的有效性和敏感性

2026-02-080
OAAI
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study
2026-02-030
OAAI
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
THE ITALIAN MAURIS PHASE IIIB TRIAL OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE FOR PATIENTS WITH NEWLY DIAGNOSED EXTENSIVE-STAGE SMALL CELL LUNG CANCER: 3-YEAR END-OF-STUDY RESULTS

意大利MAURIS 3期B研究:阿替利珠单抗联合卡铂和依托泊苷治疗新诊断广泛期小细胞肺癌的3年研究结束结果

2025-07-090
OAAI
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

III期不可切除非小细胞肺癌接受度鲁瓦姆布巩固治疗后后续治疗策略的真实世界结局

2025-06-010
OAAI
CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization
HELIYON
IF3.6
2024-08-010
OAAI
CXCL12-loaded-hydrogel (CLG) in vivo modifies lung metastatic niche toward an immunoactive microenvironment reducing lung metastasis development
2024-03-220
PRE
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
LANCET
IF88.5
2023-12-0113
PRE
Impact of immunological alterations and post-operative biomarkers on long-term outcomes in patients with locally advanced rectal cancer: Results from the STAR-01 study cohort
2023-10-010
OAAI
Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study
2023-07-0112
PRE
Immunotherapy Assessment: A New Paradigm for Radiologists

免疫治疗评估: 放射科医生的新范式

2023-01-133
OAAI
Lurbinectedin in small cell lung cancer
2022-08-3015
OAAI
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

阿特珠单抗与化疗治疗高血液肿瘤突变负荷的晚期或转移性NSCLC: BFAST队列C随机3期试验的初步分析

2022-08-2263
OAAI
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
2022-01-215
OAAI
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer
2022-01-0110
OAAI